Dianthus Therapeutics (DNTH) Net Income towards Common Stockholders: 2017-2025
Historic Net Income towards Common Stockholders for Dianthus Therapeutics (DNTH) over the last 7 years, with Sep 2025 value amounting to -$36.6 million.
- Dianthus Therapeutics' Net Income towards Common Stockholders fell 43.90% to -$36.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$125.5 million, marking a year-over-year decrease of 87.03%. This contributed to the annual value of -$84.5 million for FY2024, which is 94.65% down from last year.
- As of Q3 2025, Dianthus Therapeutics' Net Income towards Common Stockholders stood at -$36.6 million, which was down 16.20% from -$31.5 million recorded in Q2 2025.
- Dianthus Therapeutics' 5-year Net Income towards Common Stockholders high stood at -$7.1 million for Q1 2023, and its period low was -$36.6 million during Q3 2025.
- In the last 3 years, Dianthus Therapeutics' Net Income towards Common Stockholders had a median value of -$17.5 million in 2024 and averaged -$20.5 million.
- Data for Dianthus Therapeutics' Net Income towards Common Stockholders shows a maximum YoY plummeted of 165.66% (in 2024) over the last 5 years.
- Dianthus Therapeutics' Net Income towards Common Stockholders (Quarterly) stood at -$10.1 million in 2022, then dropped by 4.57% to -$10.5 million in 2023, then plummeted by 165.66% to -$27.9 million in 2024, then slumped by 43.90% to -$36.6 million in 2025.
- Its last three reported values are -$36.6 million in Q3 2025, -$31.5 million for Q2 2025, and -$29.4 million during Q1 2025.